Albert J. Siemens, PhD
Chair, FHI Foundation
Albert John Siemens has served on the Foundation’s Board of Trustees since May of 2014, and was elected as its Chair in November 2014. He joined FHI 360 in 1983 with responsibility for the organization’s Clinical Trials Division. In 1998, Dr. Siemens was appointed as the Chief Executive Officer, a position he held until retirement on May 1, 2014.
In 1986, as Vice President of Research, he was instrumental in the formation of Clinical Research International (CRI) an affiliate of FHI 360, which provided research services to pharmaceutical, biotechnology, and medical device companies. He was President of CRI until the company was acquired by ClinTrials Research in late 1990. As Executive Vice President of ClinTrials Research from 1991 through 1997, he was responsible for the international corporate expansion and business development. He was elected to the Board of Directors of FHI 360 in 1997 and as Chair of the Board in 2006.
Dr. Siemens’ career in medicinal product development began at Pfizer, Inc., where he was responsible for clinical studies of cardiovascular, antibiotic, anti-inflammatory and psychotropic agents in domestic and international divisions of the company. His pharmaceutical background is augmented by seven years of research management and teaching experience in pharmacology at the Research Institute on Alcoholism and the State University of New York at Buffalo.
Dr. Siemens holds BSc (Pharmacy) and MS degrees from the University of Manitoba, and a Ph.D. in Pharmacology from the University of Toronto. He is a member of the American Society of Clinical Pharmacology and other professional associations and has published on a range of subjects including the drug development process, drug metabolism, drug interactions, drug tolerance, membrane pharmacology, and contraceptive evaluation.